Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Industry context: pulmonary vascular disease

Industry context: pulmonary vascular disease

A rare-disease market with orphan incentives, high treatment costs and a small, heavily studied patient population.

Right heart and pulmonary circulation

The commercial structure

Pulmonary arterial hypertension is a rare disease, and its therapeutics carry orphan designation in major jurisdictions. That brings development incentives — protocol assistance, fee reductions, market exclusivity — and the high per-patient pricing characteristic of small populations.

Specialist centre care means a concentrated prescriber base, which shapes how evidence is disseminated and how trials recruit.

What drives activity

Combination therapy as standard of care, which raises the bar for new agents that must now show benefit on top of existing treatment. Device and interventional approaches. Diagnostics aimed at earlier detection, since late diagnosis remains a major contributor to poor outcomes.

Evidence generation in a rare disease

Small populations constrain trial design. Expect registries, single-arm studies with external controls, adaptive designs and enrichment strategies — each carrying assumptions that should be stated rather than assumed benign.

External control arms in particular require careful justification: the comparator population, its era and its management differ from the trial population in ways that bias comparison.

Registry evidence is observational and subject to selection by centre, so registry-based survival comparisons are not treatment effect estimates.

Reading claims in this area

Check whether a trial was placebo-controlled or added to background therapy, since the two answer different questions. Check whether the endpoint was clinical worsening or a surrogate. Note funding and author role, which are near-universal industry here, and check registration for outcome switching.

In short

What to take from this.

  • Check: placebo-controlled or add-on to background therapy — different questions.
  • External control arms need explicit justification of comparability.
  • Registry survival comparisons are not treatment effects.

Sources

  • Orphan drug regulatory frameworks (EMA, FDA)
  • Methodological literature on external controls and registry-based comparison

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.